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Galactose-deficient IgAl in sera of IgA nephropathy patients is present
in complexes with IgG. IgAl proteins from sera of patients with IgA
nephropathy (IgAN) are galactosylated to a lesser degree than those from
healthy controls. The increased reactivity of intact or de-sialylated serum
IgAl with N-acetylgalactosamine (GalNAc)-specific lectins, Helix aspersa
(HAA) and Caragana arborescens (CAA) and de-sialylated IgAl with
Helbcpomatia (HPA) and Bauhiniapurpurea (BPA) indicated that the Gal
deficiency is in glycans located in the hinge region of IgA1 molecules.
De-sialylated IgA from sera of 81 IgAN patients bound biotin-labeled
lectin HAA more effectively than did de-sialylated IgA from 56 healthy
controls (P < 0.0001). Similar results were observed for 67 IgAN patients
and 52 controls with second lectin, CAA (P < 0.00 1). The binding patterns
for 9 patients with mesangial proliferative glomerulonephritis of non-IgA
origin were similar to those for controls. Incompletely galactosylated IgAl
capable of binding GaINAc-specific lectins was detected in complexes with
IgG as demonstrated by ELISA, size-exclusion chromatography and
sucrose gradient ultracentrifugation. The formation of IgAl-IgG com-
plexes may affect the serum level of IgAl by reducing the rate of its
elimination and catabolic degradation by the liver.
IgAN nephropathy (IgAN) is the most common glomerulone-
phritis worldwide [1—4]. The disease is characterized by deposi-
tion of IgA of the IgAl subclass in the kidney mesangia in all
patients, and by elevated serum levels of IgA, IgAl-immune
complexes (IC) and IgAl-rheumatoid factor (IgAl-RF) in ap-
proximately one-half of patients [1—6]. Increased serum levels of
IgAl and IgAl-IC, with deposition in the mesangium and skin,
have been described also in diseases related to IgAN, such as
dermatitis herpetiformis (DH) and Henoch-Schönlein purpura
(I-iSP) [7, 8]. Although elevated levels of IgA, IgA-IC and/or
IgA-RF have been detected in many other diseases (such as
AIDS, IgA multiple myeloma, rheumatoid arthritis [RA], psoria-
sis, and Kawasaki's, Behcet's, and celiac diseases), IgA mesangial
deposits are usually absent [9—12]; in alcoholic liver disease and
systemic lupus erythematosus (SLE) such deposits arc relatively
frequent [13, 14]. Mechanisms for the mesangial deposition of
IgAl preferentially in patients with IgAN, DH, and HSP corn-
pared to patients with other diseases with elevated IgA, IgA-IC,
and IgA-RF are unknown [3, 15].
Pathogenesis of IgAN may be associated with overproduction
of polyclonal or antigen-specific IgAl and/or its defective clear-
ance [reviewed in 4, 15, 16]. However, mere overproduction of
IgAl due to excessive stimulation is unlikely to be the cause of
IgAl-IC deposition in tissues: high plasma levels of IgAl in
multiple myeloma do not result in tissue deposition and IgA-IC
are found only rarely [11]. Furthermore, patients with AIDS share
several common features with patients with IgAN, such as in-
creased serum levels of IgAl, IgAl-RF and IgAl-IC that appar-
ently are composed of identical components (IgAl-IgG-C3) [9,
17, 18]; however, tissue deposition of IgAl is a prominent feature
in patients only with IgAN, not with AIDS [10, 17, 181. Thus,
defective clearance of IgAl and/or IgAl-IC in IgAN but not
AIDS may be implicated in the tissue deposition. Defective
clearance may involve alterations in receptors responsible for the
catabolism of IgAl or alterations in the ligand—IgAl.
As demonstrated in vivo (both in mice and primates) and in
vitro (human hepatoma cell line Hep G2) the liver accounts for
most of the catabolism of IgA1 [19—22]. These studies revealed
that hepatocytes and, to a lesser degree, nonparenchymal cells
internalize and degrade IgA1 [20]. The asialoglycoprotein recep-
tor (ASGP-R), which recognizes terminal galactose (Gal) residues
on glycoproteins, was identified as the principal IgA receptor [19,
20], and a clear preference for IgAl and especially its carbohy-
drate-rich hinge region was noted [20, 23]. Studies performed in
patients with IgAN suggest that alterations in IgAl receptors are
unlikely because radiolabeled IgAl injected into patients with
IgAN was cleared normally [24]. The second possibility, aberrant
glycosylation pattern of the glycan moiety on IgAl from IgAN
patients, has been suggested in several recent studies [25—30]. In
this communication, we present evidence that a small population
of IgAl molecules is Gal deficient in 0-linked glycans of the IgA1
hinge region and that such aberrant IgAl molecules form IC with
IgG.
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METHODS
Human subjects
Sera from 123 biopsy-proven IgA nephropathy (IgAN) patients
(84 males, 39 females, age 33.9 14.4 years) and 9 patients with
mesangial proliferative glomerulonephritis (GN) of non-IgA ori-
gin (4 males, 5 females, age 32.0 10.0 years) were collected at
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University of Alabama at Birmingham Hospital, at the Institute
for Clinical and Experimental Medicine, Prague, and at Palacky
University, School of Medicine, Olomouc, Czech Republic. Sera
from 104 healthy volunteers with comparable sex and age distri-
bution were collected at the University of Alabama at Birming-
ham. Sera were used for isolation of IgAl used in carbohydrate
analyses (17 IgAN and 60 control), studies of IgAl reactivities
with lectins (81 IgAN and 56 control) and interactions of HAA
with IgA-IgG complexes (46 IgAN and 39 control). Sera from 21
IgAN patients and 51 controls were used in more than one study.
Six IgAl and one IgA2 myeloma proteins were isolated from
plasma of 7 patients with IgA myeloma, 1gM was obtained from
the plasma of a patient with Waldenström's macroglobulinemia
and IgG was from pooled normal human serum.
Clinical presentation of IgA nephropathy and other renal
diseases was evaluated according to duration from clinically
apparent onset, maximal and current proteinuria, hematuria,
serum creatinine concentration, rate of increase of serum creati-
nine (expressed as the mean increase per year; the difference
between the first and last serum creatinine was divided by the
number of years of follow-up), and blood pressure. Renal biopsy
findings were evaluated semiquantitatively according to the de-
gree of mesangial hypercellularity and sclerosis, percentage of
sclerotic glomeruli, presence of extracapillary proliferation, grade
of tubular atrophy and interstitial sclerosis and degree of arterio-
sclerosis. The extent of IgA, IgG, 1gM and C3 in mesangial
deposits was evaluated by immunofluorescence microscopy [29].
Isolation of serum and myeloma IgAl
IgAl from sera of IgAN patients and controls was isolated by
affinity chromatography on a column with monoclonal anti-IgAl
antibody (Clone NI 69-11, Nordic, Tilburg, The Netherlands)
immobilized on CNBr-activated Sepharose 4B (Sigma Chemical
Company, St. Louis, MO, USA). The specificity of this reagent
was extensively tested in a battery of immunochemical tests [31,
32]. IgAl was eluted from the affinity column at pH 3. Following
neutralization with sodium bicarbonate, the solution was desalted
by gel-filtration on a column of Sephadex G25, equilibrated with
phosphate-buffered saline [33]. The results indicated that the first
set of preparations contained human IgG. Therefore, in the
second set IgAl isolated by this procedure was further purified by
affinity chromatography on a column with immobilized staphylo-
coccal protein G (Sigma) to remove IgG contaminants.
Monomeric and polymeric IgAl and polymeric IgA2 myeloma
proteins were isolated by standard methods [34] which included
ammonium sulfate precipitation, gel-filtration, starch-gel electro-
phoresis [34], affinity chromatography on jacalin [29, 35] and
immunoabsorption [34]. Jacalin conjugated to agarose (Pierce,
Rockfort, IL, USA), and protein G immobilized to agarose
(Sigma Chemical Company) were purchased.
Modification of the carbohydrate moiety of IgA
N-acetylneuraminic acid (NeuNAc) residues linked to Gal or
N-acetylgalactosamine (GaINAc) on IgAl were cleaved with
neuraminidase from Vihrio cholerae (Boehringer-Mannheim, In-
dianapolis, IN, USA) or neuraminidase cloned from Clostridium
perfringens and expressed in Escherichia coli (New England Bio-
Labs, Beverly, MA, USA). Gal residues linked to GaINAc in the
hinge region of IgAl were cleaved either with /3-galactosidase
from bovine testes (Boehringer-Mannheim) which hydrolyzes
/31,3 linkages substantially faster than /31,4 or /31,6 linkages to
G1cNAc [36] or with highly specific /31,3-galactosidase from
Xanthomonas manihotis (New England BioLabs). IgAl prepara-
tions de-galactosylated in the hinge region were separated from
galactosylated IgAl by affinity chromatography on a column of
immobilized jacalin (a lectin specific for Gal(/31-3)GaINAc gly-
cans; Pierce, Rockford, IL, USA). Neuraminidase, /31,3 galacto-
sidase from bovine testes or X manihotis and liberated monosac-
charides were separated from IgA by gel-filtration through a
column of Superdex PG (Pharmacia Biotech, Piscataway, NJ,
USA). The effect of glycosidase treatment of IgAl was tested by
gas chromatography (see below).
Interactions of biotinylated lectins with serum IgAl
Wells of microtiter plates were coated with F(ab')2 fragment of
goat anti-human IgA (a chain-specific; Organon Teknika Corp.,
Westchester, PA, USA). Following washing and blocking of free
active sites with bovine serum albumin (BSA) in PBS (pH 7.3)
containing 0.05% Tween 20, the test sera diluted in the same BSA
and Tween-containing buffer were added to the wells. After
overnight incubation at 4°C, the test sera were removed, wells
were washed with Tween-containing buffer, then filled with 100 .tI
of sodium acetate buffer, pH 5, containing 10 mU/mi of V.
cholerae neuraminidase. Following incubation at 37°C for three
hours the neuraminidase-containing buffer was discarded, wells
were washed with Tween-containing buffer; the modified captured
IgA was incubated for two hours at 37°C with biotinylated lectins
(EY Laboratories, San Mateo, CA, USA): Bandeiraea simplicifo-
ha [N-acetylglucosamine (G1cNAc)-specific], Triticum vulgaris
(GlcNAc), Lens culinaris [a mannose (aMan)], Pisum sativum
(aMan), Ricinus communis (RCA 120) (/3Gal), Helix aspersa
(HAA) (Ga1NAc), Helix pomatia (HPA) (GaINAc), Caragana
arborescens (CAA) (Ga1NAc), Dolichos bifiorus (GaINAc), Gly-
cine max (GalNAc), Vicia villosa (GalNAc), Wisteria floribunda
(GalNAc), Bauhinia purpurea (BPA) (GaINAc, Gal), Artocatpus
integrifolia (AlA, jacalin), [Gal(f31-3)GaINAc], and Agaricus
bisporus [GaI(/31-3)Ga1NAc]. Titration studies have shown that
under conditions described above the optimal dilution of these
lectins was 1:500. After subsequent washing, the wells were
incubated with avidin-alkaline phosphatase (AP) (1:8000); after
additional washings they were incubated with the phosphatase
substrate (Avidin-AP and phosphatase substrate were purchased
from Sigma). The OD at 405 nm was determined in an ELISA
reader (Titertek Multiscan, ICN Biochemicals, Irvine, CA, USA).
We also tested interactions of GaINAc-specific lectins with
IgG-IgAl complexes. Wells of microtiter plates were coated with
IgG binding staphylococcal proteins A or G. After blocking with
BSA-PBS-Tween the wells were incubated with the diluted test
serum, then treated with neuraminidase as described above.
Reagents used in this study, protein A and protein G were
purchased from Sigma.
Size exclusion chromatography of serum proteins
To determine the molecular form of IgAl proteins reacting
with GaINAc-specific lectins, sera from IgAN patients and con-
trols were subjected to size exclusion chromatography by HPLC
and by preparative ultracentrifugation in sucrose gradient as
described [37]. Fractions were tested by ELISA for the content of
1gM, IgAl, IgG and proteins reacting with HAA. HPLC analyses
were conducted using Perkin Elmer (Series 10) HPLC equipped
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with a BioSep-SEC-S3000 column (600 X 7.8 mm; Phenomenex,
Torrance, CA, USA) equilibrated with 0.02 M phosphate, 0.05 M
Na2SO4, pH 6.7. Biotinylated polyclonal antibodies to 1gM and
IgG (both heavy chain-specific) and alkaline phosphatase-conju-
gated monoclonal anti-IgAl reagent used in the ELISA assay
were purchased from Southern Biotechnology (Birmingham, AL,
USA).
Carbohydrate analyses
The monosaccharides were determined as trifluoroacetates of
methyl-glycosides by gas chromatography [38], with a few modi-
fications. Aliquots of IgA and IgG preparations (20 and 50 g,
respectively) were processed and derivatized with a mixture of
ethylacetate and trifluoroacetic anhydride (85:15) in 500 tl teflon-
capped reagent vials. The analyses were performed with a
Hewlett-Packard model 5890 gas chromatograph equipped with a
25 m fused silica (0.22 mm inner diameter) OV-1701 WCOT
column, electron capture detector and a HP model 3396 integra-
tor.
Radioiodination
Proteins were radiolabeled with carrier-free Na'251 (Amersham
Corp., Arlington Hights, IL, USA) by the lactoperoxidase method
[39]. The excess free Na1251 was separated from the protein by
gel-filtration on a column of Sephadex G25. The radioactivity was
determined in Packard model 5110 y spectrometer.
Statistical analyses
Comparison between group means were performed using Stu-
dent's t-test. P values equal to or less than 0.05 were considered
statistically significant.
RESULTS
Deficient galactosylation of IgAl from sera of IgAN patients
IgAl proteins isolated from sera of 11 IgAN patients and 10
healthy volunteers by affinity chromatography on monoclonal
anti-IgAl columns were subjected to carbohydrate analyses by
gas-liquid chromatography. Results shown in Table 1 indicated a
statistically significant (P = 0.0014) difference in the content of
Gal but not other monosaccharides. Because immunochemical
tests (ELISA) of the purity of the isolated IgAl indicated the
presence of IgG, preparations of IgAl from another group of 6
patients and a pooled sample from 50 healthy individuals were
absorbed on immobilized protein G to remove IgG. After this
step, no significant differences in the Gal content were detected
between IgAl from this group of 6 patients and IgAl from all 11
controls. Because of the convincing specificity of the anti-IgAl
reagent [321, we considered the possibility that the lgG in IgAl
preparations was present in complexes composed of IgAl and IgG
(see below). To determine the localization of Gal-deficient site,
we used a battery of lectins specific for terminal mono- or
oligosaccharides in 0- and N-linked carbohydrate side-chains.
Gal deficiency is restricted to 0-linked glycans of the
IgAl hinge region
To eliminate a possible interference by intact IgG molecules in
lectin binding and the frequent presence of IgAl RF in IgAN
patients' sera, microtiter plates were coated with an F(ab')2
fragment of anti-IgA [5] and incubated with sera from 10 IgAN
Table 1. Carbohydrate composition of IgAl from sera of IgAN patients
and controls (Residues per monomeric IgAl)
A
IgAN
(N= 11)
A'
Control
(N= 10)
B
IgAN(N=6)
B'
Control
(N= 1)
Fuc 2.4 1.19 2.47 1.11 2.22 0.64 2.44
Gal 11.45 1.60a 13.82 1.40 13.32 0.86 14.12
Man 10.18 1.47 10.54 1.45 10.88 0.95 10.93
G1cNAc 13.26 1.42 14.08 1.61 13.9 1.37 14.58
Ga1NAc 6.97 1.48 7.32 1.07 7.93 0.54 8.17
NeuNAc 6.20 1.02 6.65 0.61 6.81 0.43 6.44
A and A' are IgAl from IgAN patients and controls, respectively,
purified by affinity chromatography on immobilized monoclonal anti-
IgAl; contaminated with IgG. B and B' are IgAl from IgAN patients and
pooled sera from 50 healthy individuals, respectively, purified by affinity
chromatography on immobilized anti-IgAl and successively on immobi-
lized protein G to remove IgG.
aP < 0.0014 vs. A', by Student's t-test
patients and 10 healthy controls. The bound IgA was analyzed for
reactivity with lectins specified in Table 2. When intact IgAl was
allowed to react with these lectins a statistically significant differ-
ence between the two groups was noted when Ga1NAc-specific
lectins, HAA and CAA, were used (P = 0.0228 and 0.0405,
respectively). The binding affinity of HAA and CAA to IgAl from
IgAN patients and controls increased when the IgA bound to the
F(ab')2 fragment of anti-IgA in wells of microtiter plate was
incubated with neuraminidase in acetate buffer, pH 5. We have
determined that this procedure does not alter the amount of IgAl
bound in wells. The differences of the HAA and CAA binding to
de-sialylated IgAl from IgAN patients and controls were greater
than those observed when these lectins bind to intact IgAl from
both groups (P = 0.0036 and 0.0085) (Table 2). Furthermore, the
removal of sialic acid enhanced interactions of IgAl from IgAN
patients and controls with additional lectins which did not differ in
their ability to bind intact IgA from both groups. Statistically
significant differences in binding to IgAl from both groups were
observed when de-sialylated serum IgA was incubated with Gal-
NAc-specific lectins HPA (P = 0.0298) and BPA (P = 0.004;
Table 2). Other lectins, including some with putative GalNAc
specificity, did not display significant binding differences between
the two groups. Because Ga1NAc occurs only in oligosaccharides
of the hinge region of IgAl (and not in IgA2 or IgG) [40], we
concluded that the enhanced reactivity of GalNAc-specific lectins
is due to the deficiency of Gal in the 0-linked side-chains of the
hinge region of IgAl. Structural studies have shown that glycans
in the hinge region of IgAl are present as mono- di- tn- and
tetrasaccharides [41], linked to serine (Fig. 1). Gas chromato-
graphic analyses and lectin studies of IgAl proteins from IgAN
patients and controls indicated variations in the relative propor-
tion of these structures. Increased reactivity of GalNAc-specific
lectins with intact or de—sialylated IgAl from IgAN patients
suggest increased proportion of structures containing mono- or
disaccharide with terminal NeuNAc (Fig. 1, structures D and E).
To confirm the relationship between the structure of IgAl hinge
region glycans and binding of GalNAc-specific lectins to IgAl
from IgAN sera, several IgAl myeloma proteins were subjected to
sequential treatment with neuraminidase and f31,3-galactosidase
(to remove NeuNAc and I3Gal linked to GalNAc) and examined
for their binding with lectins. The native IgAl myeloma protein
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Table 2. Reactivity of lectins with de-sialylated serum IgAl from IgAN patients and controls
Lectin Report specificity
IgANN = 10
Controls
N = 10 Significance
Bandeiraea simplicifolia (BS II) GIcNAc 0.033 0.019 0.027 0.017 NS
Triticum vulgaris GIcNAc, (GIcNAc)n 0.253 0.070 0.232 0.132 NS
Lens culinaris aMan 0.052 0.012 0.041 0.011 NS
Pisum sativum aMan 0.062 0.027 0.053 0.025 NS
Ricinus communis (RCA 120) f3Gal 1.268 0.060 1.318 0.243 NS
Helix aspersa (FIAA) GaINAc 0.683 0.111 0.494 0.139 P = 0.0036
Helix pomatia (HPA) GaINAc 0.391 0.166 0.233 0.132 P = 0.0298
Caragana arborescens (CAA) GaINAc 1.211 0.171 0.961 0.205 P 0.0085
Dolichos bifiorus GaINAc 0.035 0.020 0.835 0.311 NS
Glycine max GaINAc 0.010 0.007 0.005 0.008 NS
J/icia villosa GalNAc 0.074 0.039 0.048 0.028 NS
Wisteria floribunda GalNAc 0.115 0.049 0.075 0.056 NS
Bauhinia purpurea (BPA) GalNAc and Gal 1.642 0.148 1.213 0.383 P = 0.004
Artocarpus integrifolia (AlA) Gal p1-3 GaINAc 0.069 0.032 0.121 0.074 NS
Agaricus bisporus Gal f31-3 Ga1NAc 0.084 0.025 0.087 0.042 NS
The lectin binding assays were conducted as described in the Methods section. Test sera in all assays were diluted 1:10. OD at 405 nm were recorded
after 30—90 mm incubation of the assay mixture with p-nitrophenyl phosphate substrate; NS, not significant.
(Kni) reacted with two GalNAc-specific lectins (HAA and HPA)
relatively poorly (Table 3). The binding substantially increased
after removal of NeuNAc and even more after removal of
NeuNAc and Gal. Similar results were obtained with five other
myeloma proteins that were allowed to react with I-IAA or CAA
(data not shown). Furthermore, partial removal of the Gal from
hinge region glycans decreased the binding of the IgAl myeloma
protein to agarose-immobilized AlA (jacalin), a lectin specific to
Gal(1—3)GaINAc (Fig. 2). This observation suggested that Gal-
deficient IgAl from IgAN patients should bind to jacalin less
effectively than IgAl from controls, as previously reported 25,
26]. In the present study the decreased binding of biotinylated
jacalin to intact or de—sialylated IgAl from IgAN patients was
apparent. However, the difference between the jacalin binding to
IgAl from patients and controls was not statistically significant
(Table 2). This finding may be associated with a relatively low
avidity of jacalin toward degalactosylated IgA under the condi-
tions of this assay.
Increased reactivity of IgA from IgAN patients with
GaINAc-specific lectins
De-sialylated IgA from sera of 81 IgAN patients bound biotin-
labeled lectin HAA more effectively than did de-sialyated IgA
from 56 healthy controls (P < 0.0001). Similar results were
observed for 67 IgAN patients and 52 controls with second lectin,
CAA (P < 0.001). IgAl from sera of patients with IgAN bound
these lectins more effectively than did IgAl from patients with
mesangial proliferative glomerulonephritis of non-IgA origin
(Table 4),
No correlation was found between the magnitude of binding of
lectins listed in Table 4 to IgAl and clinical presentation of IgAN:
the duration of the disease, maximal and current proteinuria,
magnitude of microscopic hematuria, serum creatinine concentra-
tion, rate of serum creatinine increase and blood pressure.
Likewise, no correlation was observed between the lectin binding
and morphological parameters such as the degree of mesangial
hypercellularity, percentage of sclerotic glomeruli, presence of
extracapillary proliferation, grade of tubular atrophy and intersti-
tial sclerosis, and the degree of arteriosclerosis. Furthermore, the
lectin binding did not correlate with age or gender.
Among 123 patients with IgAN were three members of a single
family (mother and two daughters); all three displayed a similarly
increased binding of HAA, well above the mean value for the
whole group of IgAN patients.
Gal-deficient IgAl is complexed with IgG
The differences in the Gal content of serum IgAl purified by
affinity chromatography on immobilized monoclonal anti-IgAl, or
by the same procedure with subsequent removal of IgG by protein
G, suggested that Gal-deficient IgAl was in immune complexes
with IgG. To provide evidence for this contention, microtiter
plates were coated with protein A and protein G (both binding
IgG), incubated first with sera from IgAN patients or controls and
subsequently with biotinylated HAA. IgG bound to protein A and
G was complexed with IgAl deficient in Gal because it reacted
with GaINAc-specific lectin (HAA) (Table 5). The differences in
the amount of HAA bound to IgAl complexed with IgG from
IgAN patients and controls were statistically significant (P < 0.01
when bound to protein A; P < 0.001 when bound to protein G).
Gal-deficient IgAl in complexes with IgG was also detected in
HPLC fractions obtained by size-exclusion chromatography of
serum specimens from IgAN patients and healthy controls. The
distribution of IgAl, IgG, 1gM and protein reacting with HAA in
these fractions have shown that the highest reactivity with HAA
occurred in high molecular mass fractions containing both IgAl
and IgG, while the reactivity with fractions containing monomeric
IgG or monomeric and dimeric IgA was considerably diminished
(Fig. 3). Analogous results were obtained using fractions of
IC-enriched preparations of sera from IgAN patients separated by
HPLC and sucrose-density centrifugation (data not shown).
Therefore, we concluded that Gal-deficient IgAl which displays
high reactivity with HAA is preferentially complexed with IgG.
Although quantitatively different, parallel experiments with sera
of normal volunteers yielded similar distribution of IgG, IgA, 1gM
and HAA reactivity.
DISCUSSION
We found that IgAl from sera from patients with IgAN is
deficient in Gal and that this Gal deficiency occurs in glycans
located in the hinge region of the molecule. The hinge region is a
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NeuNAc NeuNAc
a2,3
a2,3
Gal Gal Gal
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Ser Ser Ser
D
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a1-0-
Ser
E
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a2, 6
GalNAc
a 1-0-
Ser
Fig. 1. Possible structures of 0-linked glycans in the hinge region of
human IgAl. The presence of structures A to D in the hinge region of
IgAl has been reported [65]. The increase in binding of Ga1NAc-specific
lectins to 1gM after removal of NeuNAc suggests the presence of
structure E, which has been identified in mammalian submaxillary mucins
and other glycoproteins [66].
Table 3. Interactions of HAA and HPA with native and modified
myeloma IgAl (OD 405 nm after 15 mm incubation with the substrate)
0 10 20
Native De-sialylated
De-sialylated and
f31,3-de-galactosylated
HAA
1:2000 0.071 0.193 1.018
1:250 0.153 0.703 1.701
CAA
1:2000 0.053 0.121 0.942
1:250 0.091 0.597 1.423
8000
6000
40000
2000
0
Fraction number
Fig. 2. Binding of myeloma IgAl with modified glycans to immobilized
jacalin. Radioiodinated myeloma IgAl with intact (S), de-sialylated (0),
and de-sialylated and de-galactosylated (Li) hinge region glycans (2
mg/20,000 CPM) in 0.5 ml PBS, 0.1% BSA was applied to three columns
packed with Jacalin conjugated to agarose (0.7 X 1.3 cm), equilibrated
with the same buffer. Bound IgAl was eluted with 0.1 M mellibiose in
PBS-BSA. The radioactivity was determined in 0.5 ml fractions.
these lectins bound more effectively to de-sialylated IgAl from
IgAN patients than controls. These data suggested that IgAl from
IgAN patients more frequently contains glycans in which Neu-
NAc is bound to GaINAc by a2,6 linkages (Fig. 1, structure E).
The existence of such a disaccharide would be consistent with the
data of gas-chromatographic analyses that showed a decreased
content of Gal but an unchanged content of NeuNAc in IgAl
from IgAN patients. Consecutive or parallel treatment of IgAl
myeloma proteins or IgAl from IgAN patients with neuramini-
dase and f31,3-galactosidase also further increased the binding of
Ga1NAc-specific lectins by serum IgAl from controls and IgAN
patients.
The data of our present study indicate that in sera of IgAN
patients, as well as in controls, the under-galactosylated IgAl
molecules are bound with IgG in high molar mass complexes. This
conclusion is based on the following findings: First, carbohydrate
analyses of IgAl purified by affinity chromatography on anti-IgAl
immunosorbents, with or without subsequent removal of IgG by
protein G, revealed Gal-deficient IgAl in the latter preparations.
Second, components from sera of IgAN patients and controls
incubated in wells of microtiter plates coated with protein A or
protein G reacted with lectins specific for GalNAc, indicating the
presence of IgA-IgG complexes. The amount of these lectins
bound to de-sialylated IgA-IgO complexes was significantly higher
in IgAN patients than in controls. Finally, the reactivity with a
GalNAc-specific lectin, HAA, was associated mainly with high-
molecular mass fractions of human sera separated by size exclu-
sion chromatography on HPLC or by sucrose-gradient ultracen-
trifugation; free monomeric or dimeric IgA was less reactive. The
specificity of IgG antibodies bound in these complexes with IgAl
protein was not conclusively determined.
The incomplete galactosylation of hinge region glycans may
result from a deficiency or structural aberration of an enzyme
f31,3-galactosyltransferase (131,3-GT) that mediates the transfer of
UDP-Gal to an acceptor, such as GalNAc-Ser in IgAl-producing
cells. Although considerable information is available about
Wells of microtiter plates were coated with intact IgAl and IgAl with
de-sialylated and de-sialylated and de-galactosylated hinge region glycans.
Following blocking with BSA the wells were incubated with biotinylated
I-IAA and CAA at two dilutions. The colorimetric reaction was performed
as described in the Methods section.
fragment of the al heavy chain rich in Pro, Ser, and Thr residues
[41], and contains four to five 0-linked mono- or oligosaccharides
[42—44]. In contrast to many other serum glycoproteins, including
IgD, in which four of the five 0-linked side-chains in the hinge
region are linked to Thr residues [45], in IgAl all 0-linked glycan
side-chains are attached to Ser [42]. Amino acid sequences similar
to that of human IgAl hinge region have not been described in
any other glycoprotein and the pattern in IgAl is explained by a
recent insertion of this sequence in the phylogenetically older a2
heavy chain [46].
An abnormal glycosylation of IgAl from IgAN patients was
previously reported by several investigators [25—30]. Some authors
[27] reported deficient galactosylation of hinge region glycans in
IgAl preparations isolated from serum of IgAN patients and
controls by affinity chromatography on immobilized jacalin. Be-
cause binding of IgAl to this lectin is mediated by interactions
with a disaccharide Gal(f31 -3)GaINAc, molecules lacking j3Gal in
hinge region glycans would not be quantitatively recovered by this
technique. The fact that these authors [27] were able to detect
deficiency of I3Gal in the hinge region of IgAl isolated from sera
by affinity chromatography on jacalin can be explained by a
limited specificity of jacalin preparations. Heterogeneity of vari-
ous jacalin preparations, with respect to specificity, and potential
differences in the patient population may also account for the
results reported earlier.
Localization of undergalactosylated glycans to the hinge region
of IgAl was indicated by increased binding of several lectins
specific for GalNAc to IgA from serum of IgAN patients. Most of
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Table 4. Binding of HAA and CAA to de-sialylated serum IgAl (OD 405 nm)
HAA
N Mean SD SignificanceP
CAA
N Mean SD SignificanceP
Controls 56 0461 0.269 — 52 1.017 0.303 —
IgA nephropathy 81 0.614 0.210 <0.0001 67 1.194 0.264 <0.001
Non-IgA mesangial
proliferative GN 9 0.546 0.145 NS 9 1.066 0.097 NS
Table 5. Interactions of HAA with de-sialylated-IgA-IgG complexes bound to protein A and protein G (OD 405 nm after 30 mm incubation with
the substrate)
Sera from
Protein A
(serum 1:250) N HAA
Protein G
(serum 1:100) N HAA
IgAN 46 0.624 0.240a 20 1.204 0l97
Controls 39 0.407 0.286 20 0.906 0.402
Wells of microtiter plates were coated with protein G and protein A, blocked with BSA and incubated for 2 hours with 100 d of diluted sera from
healthy controls and patients with IgAN. The captured serum proteins were de-sialylated by 3 hours incubation with neuraminidase in acetate buffer,
pH 5, washed and incubated for 2 hours with biotin-conjugated HAA (diluted 1:2000), then with avidin-alkaline phosphatase and phosphatase substrate.
Student t-test: a p < 0.001; b p < 0.01
Fig. 3. Distribution of 1gM, IgA, IgG and proteins reacting with HAA in
HPLC fractions of sera from IgAN patient. Serum (100 j.d, diluted 1:10
with 0.02 M phosphate pH 6.7, containing 0.05 M Na2SO4) was subjected
to size exclusion HPLC chromatography as described in the Methods
section. The distribution of IgG (0), IgAI (V), 1gM (LI) and glycoproteins
reacting with HAA (•) in 120 d fractions was determined by ELISA.
J31,4-GT involved in galactosylation of GIcNAc in N-linked gly-
cans, the properties, structure and regulation of expression of
/31,3-GT remains to be clarified. However, by analogy with an
extremely rare hematological disorder, the Tn-syndrome, this
locus may be highly sensitive to external influences [471. Detailed
molecular studies revealed that the enzyme deficiency was not due
to deletion of the 131,3-GT gene; instead, inactivation apparently
occurs. This has been demonstrated by in vitro treatment of cells
deficient in /31,3-GT by demethylating agents such as 5-azacytidin
or n-butyrate. After treatment with such agents, enzymatic activity
was restored, yielding normally galactosylated 0-linked glycans
[47]. On the other hand, detection of deficient galactosylation of
hinge region glycans in members of a family with IgAN (mother
and two daughters) suggests that the glycosylation defect, and thus
also the availability or function of /31,3-GT, may have been
genetically predisposed.
Hinge region glycans, particularly Gal residues, are involved in
binding IgAl to ASGP-R on hepatocytes [19, 20, 23, 48], a
receptor predominantly responsible for catabolic degradation of
IgAl [20—221. Although ASGP-R also recognizes GaINAc [49], it
is possible that IgG antibodies complexed to IgAl could prevent
its binding. Furthermore, large IgAl and IgG-containing IC may
not be able to penetrate fenestrae between the endothelial cells of
the liver to allow the interaction of IgA molecules with surfaces of
hepatocytes in the space of Disse [50].
Extensive studies indicate that glycan moieties of glycoproteins
participate in essential biological functions [51]. With respect to
immunoglobulins, modifications of their carbohydrate moiety
greatly influence their catabolic rate [21], binding to receptors on
various cell types [19, 20, 48, 52], the ability of IgG and IgA to
activate classical or alternative pathways of the complement
cascade [53—56], and their capacity to opsonization of bacteria for
phagocytosis [56] and inhibition of bacterial adherence [57]. IgAl
molecules display a high degree of heterogeneity with respect to
the total glycan content, number and type of oligosaccharide side
chains, composition of oligosaccharides and terminal monosac-
charides, as shown by carbohydrate analyses and lectin reactivities
[57, 58]. Such heterogeneity may reflect the variable availability or
functional properties of relevant glycosyltransferases. For exam-
ple, deficiency of Gal in N-linked glycan side chains in IgG
molecules from sera of patients with rheumatoid arthritis [60, 61]
was proposed to result from a deficiency or functional modifica-
tion of pl,4-GT, the enzyme responsible for galactosylation of
IgG in B cells [62, 63]. Similarly, deficiency of f31,3-GT in
lymphocytes or other blood elements in patients with Tn syn-
drome causes undergalactosylation of cell membrane glycopro-
teins with 0-linked glycans [47, 64]. We propose that an analo-
gous defect occurs in IgAN patients: IgAl molecules are
undergalactosylated due to the deficiency or structural modifica-
tion of f31,3-GT in IgAl-secreting cells. This undergalactosylated
IgAl may avoid uptake and subsequent catabolic degradation
mediated by ASGP-R in hepatocytes due to complexing with IgG.
Large lgAl-IgG complexes which have escaped the degradative
pathway [50], and are present in increased concentrations in circu-
lation, may be subsequently deposited in the kidney mesangium.
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